Literature DB >> 9307285

An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy.

B W Henderson1, D A Bellnier, W R Greco, A Sharma, R K Pandey, L A Vaughan, K R Weishaupt, T J Dougherty.   

Abstract

An in vivo quantitative structure-activity relationship (QSAR) study was carried out on a congeneric series of pyropheophorbide photosensitizers to identify structural features critical for their antitumor activity in photodynamic therapy (PDT). The structural elements evaluated in this study include the length and shape (alkyl, alkenyl, cyclic, and secondary analogs) of the ether side chain. C3H mice, harboring the radiation-induced fibrosarcoma tumor model, were used to study three biological response endpoints: tumor growth delay, tumor cell lethality, and vascular perfusion. All three endpoints revealed highly similar QSAR patterns that constituted a function of the alkyl ether chain length and drug lipophilicity, which is defined as the log of the octanol:water partition coefficient (log P). When the illumination of tumor, tumor cells, or cutaneous vasculature occurred 24 h after sensitizer administration, activities were minimal with analogs of log P < or = 5, increased dramatically between log P of 5-6, and peaked between log P of 5.6-6.6. Activities declined gradually with higher log P. The lack of activity of the least-lipophilic analogs was explained in large part by their poor biodistribution characteristics, which yielded negligible tumor and plasma drug levels at the time of treatment with light. The progressively lower potencies of the most lipophilic analogs cannot be explained through the overall tumor and plasma pharmacokinetics of photosensitizer because tumor and plasma concentrations progressively increased with lipophilicity. When compensated for differences in tumor photosensitizer concentration, the 1-hexyl derivative (optimal lipophilicity) was 5-fold more potent than the 1-dodecyl derivative (more lipophilic) and 3-fold more potent than the 1-pentyl analog (less lipophilic), indicating that, in addition to the overall tumor pharmacokinetics, pharmacodynamic factors may influence PDT activity. Drug lipophilicity was highly predictive for photodynamic activity. QSAR modeling revealed that direct antitumor effects and vascular PDT effects may be governed by common mechanisms, and that the mere association of high levels of photosensitizer in the tumor tissue is not sufficient for optimal PDT efficiency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307285

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy.

Authors:  Zhuo Chen; Shanyong Zhou; Jincan Chen; Yicai Deng; Zhipu Luo; Hongwei Chen; Michael R Hamblin; Mingdong Huang
Journal:  ChemMedChem       Date:  2010-06-07       Impact factor: 3.466

2.  Equilibrium and kinetic studies of the interactions of a porphyrin with low-density lipoproteins.

Authors:  Stéphanie Bonneau; Christine Vever-Bizet; Patrice Morlière; Jean-Claude Mazière; Daniel Brault
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 3.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Synthesis, spectroscopic, and in vitro photosensitizing efficacy of ketobacteriochlorins derived from ring-B and ring-D reduced chlorins via pinacol-pinacolone rearrangement.

Authors:  Penny Joshi; Manivannan Ethirajan; Lalit N Goswami; Avinash Srivatsan; Joseph R Missert; Ravindra K Pandey
Journal:  J Org Chem       Date:  2011-10-05       Impact factor: 4.354

5.  Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Authors:  C J Dimitroff; W Klohs; A Sharma; P Pera; D Driscoll; J Veith; R Steinkampf; M Schroeder; S Klutchko; A Sumlin; B Henderson; T J Dougherty; R J Bernacki
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 6.  Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells.

Authors:  Halina Mojzisova; Stéphanie Bonneau; Daniel Brault
Journal:  Eur Biophys J       Date:  2007-07-13       Impact factor: 1.733

7.  Effect of chirality on cellular uptake, imaging and photodynamic therapy of photosensitizers derived from chlorophyll-a.

Authors:  Avinash Srivatsan; Paula Pera; Penny Joshi; Yanfang Wang; Joseph R Missert; Erin C Tracy; Walter A Tabaczynski; Rutao Yao; Munawwar Sajjad; Heinz Baumann; Ravindra K Pandey
Journal:  Bioorg Med Chem       Date:  2015-04-09       Impact factor: 3.641

8.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 9.  Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents.

Authors:  Nela Malatesti; Ivana Munitic; Igor Jurak
Journal:  Biophys Rev       Date:  2017-03-24

10.  Photodynamic Therapy for Cancer and for Infections: What Is the Difference?

Authors:  Sulbha K Sharma; Pawel Mroz; Tianhong Dai; Ying-Ying Huang; Tyler G St Denis; Michael R Hamblin
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.